



22 April 2009

Eric Abadie  
European Medicines Agency  
7 Westferry Circus  
Canary Wharf  
London  
E14 4HB  
United Kingdom

**Subject:** Withdrawal of Clopidogrel Teva Pharma 75 mg film-coated tablets (clopidogrel hydrobromide)  
**Procedure number:** EMEA/H/C/001052/0000

Dear Eric Abadie,

I would like to inform you that, at this point of time, Teva Pharma B.V. has taken the decision to withdraw the application for Marketing Authorisation of Clopidogrel Teva Pharma 75 mg film-coated tablets (clopidogrel hydrobromide), which was intended to be used for the prevention of atherothrombotic events in patients suffering from myocardial infarction, ischaemic stroke or established peripheral arterial disease.

This withdrawal is based on the following reason:

– Teva Pharma B.V. has decided not to continue this application due to the company's marketing strategy.

We reserve the right to make further submissions at a future date in this or other therapeutic indication(s).

I agree for this letter to be published on the EMEA website.

Yours sincerely,

On behalf of Teva Pharma B.V.,

Teva Pharmaceuticals Europe BV

**Teva Pharma B.V.**  
Computerweg 10, P.O. Box 43028, 3540 AA UTRECHT - The Netherlands  
Phone: +31(0)346 290 250 - Fax: +31(0)346 290 299

Chamber of Commerce Utrecht 30099369, VAT NO 800 535 558 B01  
Bank: Fortis (Nederland) N.V. Account NO. 24.06.53.602, IBAN: NL63FTSB0240653602, SWIFT: FTSBNL2R